Australia markets closed

Novartis AG (NVSEF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
78.900.00 (0.00%)
At close: 03:12PM EST
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2020
31/12/2019
31/12/2018
31/12/2017
Total revenue
52,385,000
49,898,000
48,677,000
53,166,000
50,135,000
Cost of revenue
16,108,000
15,121,000
14,425,000
18,407,000
17,175,000
Gross profit
36,277,000
34,777,000
34,252,000
34,759,000
32,960,000
Operating expenses
Research development
9,464,000
8,980,000
9,402,000
9,074,000
8,972,000
Selling general and administrative
14,825,000
14,197,000
14,369,000
16,471,000
14,997,000
Total operating expenses
24,506,000
24,625,000
25,166,000
26,590,000
24,331,000
Operating income or loss
11,771,000
10,152,000
9,086,000
8,169,000
8,629,000
Interest expense
806,000
869,000
850,000
957,000
777,000
Total other income/expenses net
859,000
673,000
499,000
6,372,000
1,062,000
Income before tax
11,745,000
9,878,000
8,940,000
13,835,000
8,999,000
Income tax expense
1,934,000
1,807,000
1,793,000
1,221,000
1,296,000
Income from continuing operations
9,811,000
8,071,000
7,147,000
12,614,000
7,703,000
Net income
9,807,000
8,072,000
11,732,000
12,611,000
7,703,000
Net income available to common shareholders
9,807,000
8,072,000
11,732,000
12,611,000
7,703,000
Basic EPS
-
3.55
5.12
5.44
3.28
Diluted EPS
-
3.52
5.06
5.38
3.25
Basic average shares
-
2,277,000
2,291,000
2,319,000
2,346,000
Diluted average shares
-
2,296,000
2,319,000
2,344,000
2,371,000
EBITDA
-
17,211,000
15,616,000
21,684,000
15,852,000